Want to see VCEL full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.Company Guidance
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $68.4M in Q1 2026, up 30% year-over-year and significantly above company guidance.
MACI Outstanding Performance
MACI revenue of $56.4M (+22% YoY); trailing four-quarter MACI revenue growth increased to 23% (from 19% prior period); fourth consecutive quarter with MACI growth ≥20%; Q2 MACI guidance implying ~$62.5M–$63.5M.
Burn Care Momentum and BARDA Award
Burn Care revenue >$12M in Q1, up over 90% YoY; Epicel $10.9M and NexoBrid $1.1M (NexoBrid +~60% vs. Q4); announced BARDA award up to $197M with $35M base contract (including ~$10M in next 12 months) and expected NexoBrid procurement revenue of ~$5M–$6M in H2 2026.
Margin Expansion and Profitability Improvement
Gross margin increased by >300 basis points to 72% in Q1; adjusted EBITDA margin improved nearly 800 basis points to 14%; adjusted EBITDA was ~$9.6M (nearly tripled / +195% YoY per CFO commentary).
Strong Cash Generation and Balance Sheet
Operating cash flow of $16.4M and free cash flow of $15.1M in Q1 (third consecutive quarter with free cash flow ≥$12M); cash and investments ~ $211M, up nearly $50M vs. prior-year period.
Commercial Execution — Sales Force Expansion
First quarter operating with expanded MACI sales force produced record biopsies, implants and biopsy/implanting surgeons; implants and biopsies per surgeon accelerated, with improved biopsy-to-implant pull-through especially in new territories.
MACI Arthro Early Clinical Signals
Investigator case series shows early MACI Arthro benefits (reduced post-op pain, improved range of motion, faster time to full weight bearing); initial data accepted for publication and registry data collection underway.
Operational Milestone — Manufacturing Approval and International Pathway
FDA approval for MACI commercial manufacturing at new Burlington facility increases capacity and enables planned UK marketing application later in 2026 with potential UK launch in 2027.
Raised Full-Year Guidance
Total 2026 revenue guidance increased by $10M to $326M–$336M; MACI guidance raised to $282M–$288M; Burn Care guidance raised to $44M–$48M; company midpoint implies ~20% total revenue growth for 2026.
VCEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VCEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $36.78 | $35.13 | -4.49% |
Feb 26, 2026 | $37.09 | $37.68 | +1.59% |
Nov 06, 2025 | $37.20 | $38.75 | +4.17% |
Jul 31, 2025 | $40.66 | $34.94 | -14.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vericel Corporation (VCEL) report earnings?
Vericel Corporation (VCEL) is schdueled to report earning on Aug 05, 2026, TBA (Confirmed).
What is Vericel Corporation (VCEL) earnings time?
Vericel Corporation (VCEL) earnings time is at Aug 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCEL EPS forecast?
VCEL EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.